Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 6Tamoxifen 3Starch 1Standard of Care 1Sentinel Lymph Node Biopsy 1Restraint, Physical 1Radiotherapy 1Radiosurgery 1Probiotics 1Practice Guidelines as Topic 1Omacor 1Methods 1Mastectomy, Subcutaneous 1Laser Therapy 1Genetic Testing 1Follow-Up Studies 1Diet Therapy 1Diet 1Chromatin Immunoprecipitation Sequencing 1Cannabidiol 1Bone Density 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Carcinoma In Situ × Bone Density × Clear all
NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Mayo Clinic

Phase 2 Recruiting
38 enrolled
Breast

Breast Carcinoma In Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡